Pro-inflammatory cytokines and signaling

Pro-inflammatory cytokines and signaling encompass a broad class of signaling proteins and their associated pathways that drive the inflammatory response in the human body. Major cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) are produced primarily by activated macrophages and T-cells to coordinate immune cell recruitment and activation (StatPearls, 2023 [1]). These molecules bind to high-affinity cell-surface receptors, initiating intracellular signaling cascades—most notably the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways—which regulate the expression of genes involved in cell survival and inflammation (Nature Reviews Drug Discovery, 2018 [2]). In many pathological states, such as rheumatoid arthritis, psoriasis, and cytokine storm syndromes, these pathways become chronically or excessively active, leading to systemic tissue damage (PubMed, 2021 [3]). Consequently, this network is a primary focus of modern pharmacology, with numerous biologics and small molecules designed to neutralize specific cytokines or inhibit their downstream signaling components to restore immune homeostasis (NIH, 2022 [4]). However, because these pathways are integral to normal immune surveillance, their therapeutic suppression carries significant risks, most notably an increased susceptibility to opportunistic infections and the reactivation of latent diseases (Frontiers in Immunology, 2020 [5]). [1] https://www.ncbi.nlm.nih.gov/books/NBK545230/ [2] https://www.nature.com/articles/nrd.2017.231 [3] https://pubmed.ncbi.nlm.nih.gov/33433456/ [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151640/ [5] https://www.frontiersin.org/articles/10.3389/fimmu.2020.01064/

Other names

Inflammatory cytokinesPro-inflammatory signaling pathwaysCytokine cascadeInflammatory mediatorsCytokine storm components

Drugs targeting this system function by neutralizing circulating cytokines (monoclonal antibodies), acting as decoy receptors (fusion proteins), or inhibiting intracellular signaling enzymes such as Janus kinases (JAK inhibitors) to prevent gene transcription associated with inflammation.